Chonnam National University
Also known as: Chonnam natianl university hospital | Chonnam Natinal University Hospital | Chonnam National Univ. | Chonnam National Univeristy Hwasun Hospital | Chonnam National Universitiy Hospital | Chonnam National University | Chonnam National University Hospital | Chonnam National University Hwasun Hospital, Department of Hematology-Oncology | Chonnam National University Hwasun Hospital, Jeollanamdo, Korea | Chonnam National Universtiy Hospital of Korea | Chonnam University Hospital | CNUHH | Connam National University Hospital | Deok-Hwan Yang | Department of Anesthesiology and Pain Medicine, Chonnam National University Hospital | Dept. of Psychiatry, Chonnam National University Hospital | Heart Center of Chonnam National University Hospital
Highest phase reached
Phase 4
First clinical trial
Jul 1, 2005Last known activity
Apr 4, 2024
Timeline
1950s
- Jan 1, 1952
Chonnam National University— Founded
Drugs by trial phase (123 distinct, 102 trials)
Phase 4 (34 own, 0 via acquisition)
Phase 3 (43 own, 0 via acquisition)
Phase 2 (39 own, 0 via acquisition)
Other trials (7 own, 0 via acquisition)
Indications
Studied for
- Acute Coronary Syndrome
- Adenocarcinoma
- Adenocarcinoma of Lung
- Alcohol Drinking
- Aortic Valve Stenosis
- Arthritis
- Arthritis, Juvenile
- Arthritis, Psoriatic
- Atrial Fibrillation
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Small Cell
- Carotid Stenosis
- Cerebral Infarction
- Colorectal Neoplasms
- Constriction, Pathologic
- Coronary Artery Disease
- Coronary Disease
- Death
- Depressive Disorder
- Diabetes Mellitus
- Diabetes Mellitus, Type 2
- Diabetic Neuropathies
- Dwarfism
- Dyspepsia
- Erectile Dysfunction
- Esophagitis
- Esophagitis, Peptic
- Essential Hypertension
- Familial Primary Pulmonary Hypertension
- Gastritis
- Glioblastoma
- Glomerulonephritis
- Gonadal Dysgenesis
- Head and Neck Neoplasms
- Heart Arrest
- Heart Failure
- Hemorrhage
- Hepatitis
- Hepatitis B
- Hepatitis B, Chronic
- Hyperlipidemias
- Hyperlipoproteinemias
- Hyperplasia
- Hypertension
- Infarction
- Influenza, Human
- Ischemia
- Keratosis
- Keratosis, Actinic
- Kidney Diseases
- Leukemia
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, Lymphoid
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Leukemia, Myeloid
- Leukemia, Myeloid, Accelerated Phase
- Leukemia, Myeloid, Chronic-Phase
- Lung Diseases
- Lung Diseases, Obstructive
- Lung Neoplasms
- Lymphoma
- Lymphoma, B-Cell
- Lymphoma, B-Cell, Marginal Zone
- Lymphoma, Extranodal NK-T-Cell
- Lymphoma, Large B-Cell, Diffuse
- Lymphoma, T-Cell
- Metabolic Syndrome
- Multiple Myeloma
- Myelodysplastic Syndromes
- Myocardial Infarction
- Myocardial Reperfusion Injury
- Neoplasms
- Neoplasms, Plasma Cell
- Neuralgia
- Otitis
- Otitis Media
- Out-of-Hospital Cardiac Arrest
- Pancreatic Neoplasms
- Pleural Effusion
- Pleural Effusion, Malignant
- Premature Birth
- Premature Ejaculation
- Prostatic Hyperplasia
- Pulmonary Disease, Chronic Obstructive
- Reperfusion Injury
- Schizophrenia
- Sleep Initiation and Maintenance Disorders
- Small Cell Lung Carcinoma
- Spinal Stenosis
- Spondylitis
- Spondylitis, Ankylosing
- ST Elevation Myocardial Infarction
- Stomach Neoplasms
- Stroke
- Syndrome
- Tuberculosis
- Tuberculosis, Pulmonary
- Turner Syndrome
- Ventricular Remodeling
- Wounds and Injuries
Recent trials (50)
- NCT05827549CollaboratorPhase 2Apr 4, 2024
- NCT05590572CollaboratorPhase 1/Phase 2Jan 31, 2023
- NCT05381194CollaboratorPhase 4Dec 13, 2022
- NCT06054321Lead sponsorN/AAug 3, 2022
- NCT06054321Reponsible party - principal investigatorN/AAug 3, 2022
- NCT06054321Overall official - principal investigatorN/AAug 3, 2022
- NCT04733521Overall official - principal investigatorPhase 1/Phase 2May 1, 2021
- NCT06081803CollaboratorPhase 3Dec 5, 2020
- NCT04485156CollaboratorPhase 3Sep 30, 2020
- NCT05051332Overall official - principal investigatorPhase 3Mar 19, 2020
- NCT04214990CollaboratorPhase 3Jan 15, 2020
- NCT04059887Overall official - principal investigatorPhase 4Oct 31, 2019
- NCT04059887Lead sponsorPhase 4Oct 31, 2019
- NCT04059887Reponsible party - principal investigatorPhase 4Oct 31, 2019
- NCT04066920Overall official - principal investigatorPhase 2Oct 1, 2019
Details
- Founded
- Gwangju, KR Jan 1, 1952
- Last known activity
- Apr 4, 2024